Loading...
Docoh

Heska Corp. (HSKA)

Heska Corporation manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production under third-party agreements and channels, primarily for herd animal health.

Company profile

Ticker
HSKA
Exchange
Website
CEO
Kevin Wilson
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Diamond Animal Health, Inc. • BioTech Laboratories U.S.A. LLC • Heska AG, a corporation incorporated • Heska Canada, Limited, a limited company • Heska Australia Pty Ltd • SCI A. Duchene Immo, a real estate company • Veterinärmedizinisches Dienstleistungszentrum (VetZ) GmbH, a corporation incorporated • Heska GmbH, a corporation incorporated • scil animal care company GmbH, a corporation incorporated • scil animal care company sarl, a limited liability company ...
IRS number
770192527

HSKA stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

8 Aug 22
20 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 171.93M 171.93M 171.93M 171.93M 171.93M 171.93M
Cash burn (monthly) 272K 6.1M 1.85M 1.53M (no burn) 1.46M
Cash used (since last report) 458.08K 10.28M 3.11M 2.57M n/a 2.46M
Cash remaining 171.47M 161.65M 168.82M 169.36M n/a 169.47M
Runway (months of cash) 630.4 26.5 91.4 111.0 n/a 116.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jun 22 Catherine Grassman Common Stock Payment of exercise Dispose F No No 99.71 398 39.68K 9,140
4 May 22 Antin Robert L Common Stock Grant Acquire A No No 0 1,107 0 2,189
4 May 22 Davis Stephen L Common Stock Grant Acquire A No No 0 1,107 0 2,553
4 May 22 Furlong Mark F Common Stock Grant Acquire A No No 0 1,107 0 4,726
4 May 22 Humphrey Scott Common Stock Grant Acquire A No No 0 1,107 0 6,881
13F holders Current Prev Q Change
Total holders 160 168 -4.8%
Opened positions 17 15 +13.3%
Closed positions 25 29 -13.8%
Increased positions 69 67 +3.0%
Reduced positions 49 65 -24.6%
13F shares Current Prev Q Change
Total value 1.14B 1.61B -29.6%
Total shares 11.06M 11.04M +0.2%
Total puts 12.3K 10K +23.0%
Total calls 3.6K 8K -55.0%
Total put/call ratio 3.4 1.3 +173.3%
Largest owners Shares Value Change
BLK Blackrock 1.86M $175.8M +0.6%
Alger Associates 1.03M $187.65M 0.0%
Nine Ten Capital Management 871.79K $82.39M +4.2%
Fred Alger Management 812.6K $76.8M -19.5%
Vanguard 711.87K $67.28M +0.5%
AMP Ameriprise Financial 506.36K $47.86M +0.5%
STT State Street 384.9K $36.38M +5.7%
IVZ Invesco 373.32K $35.28M +91.9%
SLFPY Standard Life Aberdeen 353.27K $33.39M +6.8%
FMR 338.04K $31.95M +47.3%
Largest transactions Shares Bought/sold Change
Fred Alger Management 812.6K -196.46K -19.5%
IVZ Invesco 373.32K +178.74K +91.9%
Ranger Investment Management 0 -176.5K EXIT
FMR 338.04K +108.57K +47.3%
Allspring Global Investments 199.61K -91.76K -31.5%
Millennium Management 104.71K -73.63K -41.3%
Russell Investments 0 -54.1K EXIT
Grandeur Peak Global Advisors 219.93K +46.07K +26.5%
Monarch Partners Asset Management 55.34K +44.13K +393.9%
Allianz Asset Management GmbH 161.68K -43.54K -21.2%

Financial report summary

?
Competition
Idexx LaboratoriesSanofiZoetis
Risks
  • We may be held liable for the release of hazardous materials, which could result in extensive remediation costs or otherwise harm our business.
Management Discussion
  • Our analysis presented below is organized to provide the information we believe will facilitate an understanding of our historical performance and relevant trends going forward.
  • (1) See “Non-GAAP Financial Measures” for a reconciliation of Adjusted EBITDA to net income and Non-GAAP net income per diluted share to diluted loss per share attributable to Heska Corporation, the closest comparable GAAP measures, for each of the periods presented. Net (loss) income margin and adjusted EBITDA margin are calculated as the ratio of net (loss) income and adjusted EBITDA, respectively, to revenue.
  • (2) Shares used in the diluted per share calculation for non-GAAP net income per diluted share are (in thousands): 10,533 for the three months ended June 30, 2022 compared to 10,530 for the three months ended June 30, 2021 and 10,569 for the six months ended June 30, 2022 compared to 10,189 for the six months ended June 30, 2021.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: authorized, effort, explicit, extraordinary, highest, low, mandatorily, pathology, rationalization, repurchase, treated, unissued, weakening
Removed: wave